来源：新浪证券-红岸工作室 2月26日，华人健康跌1.69%，成交额2.41亿元。两融数据显示，当日华人健康获融资买入额1806.28万 元，融资偿还1836.84万元，融资净买入-30.55万元。截至2月26日，华人健康融资融券余额合计1.41亿 元。 融资方面，华人健康当日融资买入1806.28万元。当前融资余额1.40亿元，占流通市值的4.89%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，华人健康2月26日融券偿还100.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量1.76万股，融券余额33.84万元，超过近一年80%分位水平，处于高位。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康实现营业收入38.92亿元，同比增长19.06%；归母净利润1.57亿元， 同比增长45.21%。 分红方面，华人健康A股上市后累计派现8000.20万元。 机构持仓方面，截止2025年9月30日，华人健康十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股232. ...

华人健康公告称，本次上市流通的限售股份为首次公开发行前已发行的限售股份，申请解除限售的股东 共6户，解除限售股份数量为250,837,347股，占总股本比例62.71%，上市流通日期为2026年3月2日。解 除限售后，限售条件流通股占比降至42.76%，无限售条件流通股占比升至57.24%。保荐人华泰联合证 券认为本次限售股份上市流通符合相关要求，申请解除股份限售的股东已严格履行承诺。 ...

证券代码：301408 证券简称：华人健康 公告编号：2026-005 安徽华人健康医药股份有限公司 关于首次公开发行前已发行股份上市流通提示性 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次上市流通的限售股份为安徽华人健康医药股份有限公司（以下简称 "公司""发行人"或"华人健康"）首次公开发行前已发行的限售股份。 2、本次申请解除限售的股东数量共计 6 户，解除限售股份的数量为 250,837,347 股，占公司总股本比例为 62.71%，限售期为自公司首次公开发行股 票并上市之日起 36 个月。 3、本次解除限售股份的上市流通日期为 2026 年 3 月 2 日（星期一）（因 2026 年 3 月 1 日为非交易日，上市流通日顺延至 2026 年 3 月 2 日）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]2406 号）同意注册，公司获准向 社会公众发行人民币普通股（A 股）6,001.00 万股，并于 2023 年 3 ...

华泰联合证券有限责任公司关于 安徽华人健康医药股份有限公司首次公开发行前已发行股 份上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业 务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务》等有关规定，对华人健康首次公开发行 前已发行股份上市流通的事项进行了核查，具体情况如下： 核查意见 1 核查意见 自公司首次公开发行股票上市之日至本核查意见出具日，公司未发生因股份 增发、回购注销、派发股票股利或资本公积金转增等导致股本数量变化的情况。 截至本核查意见出具日，公司总股本为 400,010,000 股，其中有限售条件流 通股为 250,838,697 股，占公司总股本比例为 62.71%，无限售条件流通股 149,171,303 股，占公司总股本比例为 37.29%。 一、首次公开发行前已发行股份概 ...

来源：新浪证券-红岸工作室 2月13日，华人健康跌2.80%，成交额2.18亿元。两融数据显示，当日华人健康获融资买入额1181.63万 元，融资偿还2403.06万元，融资净买入-1221.43万元。截至2月13日，华人健康融资融券余额合计1.48 亿元。 融资方面，华人健康当日融资买入1181.63万元。当前融资余额1.48亿元，占流通市值的5.01%，融资余 额超过近一年60%分位水平，处于较高位。 资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药97.60%，其他(补充)2.40%。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康实现营业收入38.92亿元，同比增长19.06%；归母净利润1.57亿元， 同比增长45.21%。 分红方面，华人健康A股上市后累计派现8000.20万元。 机构持仓方面，截止2025年9月30日，华人 ...

Group 1: Stock Price Movement - The stock price of Huaren Health (301408) experienced a decline of 4.05% to 20.83 yuan following a share reduction announcement by major shareholder Sequoia Capital, which plans to reduce up to 8 million shares (2% of total shares) between February 5 and April 30, 2026 [1] - On February 5, 2026, the first day of the reduction plan, 104,700 shares (0.0262% of total shares) were sold [1] Group 2: Financial Position - As of February 10, 2026, Huaren Health's financing balance stood at 168 million yuan, accounting for 5.49% of its market capitalization, which is above the 80th percentile of the past year [2] - The margin balance was 359,800 yuan, exceeding the 90th percentile of the past year, indicating a high level of market activity [2] Group 3: Recent Stock Performance - For the week ending February 6, 2026, Huaren Health's stock price fell by 3.95%, with a net outflow of 120 million yuan from major funds [3] - On February 9, 2026, the stock saw an intraday increase of 2.13% to 20.63 yuan, but still experienced a net outflow of 14.65 million yuan from major funds [3] - Year-to-date, the stock price has increased by 11.15%, with a 60-day increase of 30.32%, indicating significant volatility [3]

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is focusing on enhancing its strategic partnerships and technological advancements in the healthcare sector, particularly through AI applications and e-commerce platforms [2][3]. Group 1: Company Developments - On October 23, 2025, the company established a strategic partnership with iFlytek Medical to enhance professional service efficiency in pharmacies and address user health needs through the launch of the "Pharmacy AI Health Assistant" [2]. - The company is actively investing in information technology to transition from information-based to intelligent integration, exploring suitable business scenarios for AI applications, which have improved service efficiency and customer experience [2]. - As of September 30, 2025, the company reported a revenue of 3.892 billion yuan, a year-on-year increase of 19.06%, and a net profit attributable to shareholders of 157 million yuan, reflecting a growth of 45.21% [8]. Group 2: Shareholder and Market Information - As of September 30, 2025, the company had 20,100 shareholders, a decrease of 22.86% from the previous period, with an average of 7,422 circulating shares per person, an increase of 29.64% [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company's shares, and the company collaborates with various Alibaba platforms, including Alipay and Tmall [3]. - The company has diversified its e-commerce presence, expanding its operations on major platforms such as JD.com, Pinduoduo, and Meituan, achieving significant growth during the reporting period [2].

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is actively engaging in strategic partnerships and technological advancements in the healthcare sector, particularly focusing on AI applications and e-commerce platforms to enhance service efficiency and user experience. Group 1: Company Developments - On October 23, 2025, the company established a strategic partnership with iFlytek's medical division to enhance professional service efficiency in pharmacies through the launch of the "Pharmacy AI Health Assistant" [2] - The company is investing in information technology to transition from digitalization to intelligent integration, exploring AI applications in medical services and customer experience [2] - As of September 30, 2025, the company reported a revenue of 3.892 billion yuan, a year-on-year increase of 19.06%, and a net profit of 157 million yuan, up 45.21% year-on-year [8] Group 2: Shareholder and Market Information - As of September 30, 2025, the number of shareholders decreased by 22.86% to 20,100, while the average number of circulating shares per person increased by 29.64% to 7,422 shares [8] - The company has a significant shareholder relationship with Alibaba Health, which holds 7.51% of the company's shares, and collaborates with various Alibaba platforms [3] - The company has diversified its e-commerce presence across major platforms, including JD.com, Pinduoduo, and Meituan, achieving substantial growth during the reporting period [2]

Core Viewpoint - The company, Huaren Health, has shown fluctuations in its stock performance and financing activities, indicating a high level of trading activity and potential investor interest in the healthcare sector [1][2]. Group 1: Stock Performance - On February 10, Huaren Health's stock fell by 0.77%, with a trading volume of 198 million yuan [1]. - The financing buy-in amount for Huaren Health on the same day was 16.81 million yuan, while the financing repayment was 20.47 million yuan, resulting in a net financing outflow of 3.66 million yuan [1]. - As of February 10, the total financing and securities lending balance for Huaren Health was 169 million yuan, with the financing balance accounting for 5.49% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Huaren Health reported a revenue of 3.892 billion yuan, representing a year-on-year growth of 19.06% [2]. - The net profit attributable to the parent company for the same period was 157 million yuan, reflecting a significant year-on-year increase of 45.21% [2]. Group 3: Shareholder and Dividend Information - As of September 30, 2025, the number of shareholders for Huaren Health was 20,100, a decrease of 22.86% from the previous period [2]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 2.3203 million shares, an increase of 1.3357 million shares compared to the previous period [3].

证券代码：301408 证券简称：华人健康 公告编号：2026-004 规格：25ml/袋，每袋含：聚乙二醇 3350 13.125g；氯化钠 0.3508g；氯化钾 0.0502g；碳酸氢钠 0.1786g 受理说明：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 受理号：CYHS260***7 安徽华人健康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 近日，安徽华人健康医药股份有限公司（以下简称"公司"）全资子公司江 苏神华药业有限公司收到国家药品监督管理局下发的复方聚乙二醇（3350）电解 质口服溶液药品注册上市许可申请《受理通知书》。现将相关情况公告如下： 一、《受理通知书》主要内容 申请事项：境内生产药品注册上市许可 产品名称：复方聚乙二醇（3350）电解质口服溶液 二、复方聚乙二醇（3350）电解质口服溶液的相关情况 复方聚乙二醇（3350）电解质口服溶液是一种用于治疗慢性便秘的药物，本 品缓泻的主要成分是聚乙二醇 3350，它是一种高分子聚合物，几乎 ...